Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Oct 26

PMID 39459526

Authors

Ludovico Abenavoli

Rocco Spagnuolo

Giuseppe Guido Maria Scarlata

Maria Luisa Gambardella

Luigi Boccuto

Nahum Mendez-Sanchez

Francesco Luzza

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory bowel disease (IBD) is characterized by persistent inflammation and is often associated with metabolic dysfunction-associated steatotic liver disease (MASLD). IBD patients are at risk of developing MASLD due to shared risk factors such as gut dysbiosis and systemic inflammation. The new MASLD nomenclature emphasizes the link between liver steatosis and cardiometabolic comorbidities. However, the prevalence of MASLD in IBD patients remains poorly explored. The main aim of this cross-sectional study is to assess the prevalence of ultrasound (US) and the clinical features of MASLD in patients with IBDs.

Materials And Methods: We conducted a retrospective study enrolling 272 Italian IBD patients attending Renato Dulbecco Teaching Hospital in a period between 1 January 2021 and 31 December 2023. MASLD was diagnosed based on the presence of liver steatosis with cardiometabolic risk factors, using established guidelines. Demographic, clinical, and laboratory data were collected and analyzed. Statistical significance was determined at a -value < 0.05.

Results: Of the 272 IBD patients, 6% had non-alcoholic fatty liver disease (NAFLD), while 18% had MASLD. Patients with IBD-MASLD were significantly older, had higher body mass index, waist circumference, and triglyceride levels, and were more likely to have type 2 diabetes mellitus and hypertension compared to those with IBD-NAFLD. IBD-MASLD patients also showed higher disease activity scores and required more frequent surgical interventions. Bivariate logistic regression revealed triglyceride levels as a significant predictor of MASLD in IBD patients.

Conclusions: MASLD is more prevalent in IBD patients, highlighting the importance of early detection of liver steatosis in this at-risk population. The association between MASLD and cardiometabolic risk factors underscores the need for a multidisciplinary approach to manage these patients effectively. Further studies in larger cohorts are necessary to confirm these findings and explore the pathophysiological mechanisms involved.

References

Ramirez-Mejia M, Jimenez-Gutierrez C, Eslam M, George J, Mendez-Sanchez N . Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?. Hepatol Int. 2023; 18(1):168-178. DOI: 10.1007/s12072-023-10620-y. View

Boustany A, Rahhal R, Mitri J, Onwuzo S, Zeid H, Baffy G . The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review. Eur J Gastroenterol Hepatol. 2023; 35(10):1067-1074. DOI: 10.1097/MEG.0000000000002607. View

Wu S, Yuan C, Yang Z, Liu S, Zhang Q, Zhang S . Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med. 2022; 20(1):262. PMC: 9394037. DOI: 10.1186/s12916-022-02460-8. View

Rodriguez-Duque J, Calleja J, Iruzubieta P, Hernandez-Conde M, Rivas-Rivas C, Vera M . Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin Gastroenterol Hepatol. 2022; 21(2):406-414.e7. DOI: 10.1016/j.cgh.2022.01.039. View

Sung K, Kim B, Cho Y, Park D, Woo S, Kim S . Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC Gastroenterol. 2012; 12:84. PMC: 3502272. DOI: 10.1186/1471-230X-12-84. View

Franco L, Jones-Pauley M, Tamimi O, Neshatian L, Nguyen D, Graviss E . Irritable Bowel Syndrome Symptoms in Nonalcoholic Fatty Liver Disease Patients Are an Indicator of Depression and Anxiety. J Clin Gastroenterol. 2022; 57(10):1016-1023. DOI: 10.1097/MCG.0000000000001770. View

Principi M, Iannone A, Losurdo G, Mangia M, Shahini E, Albano F . Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflamm Bowel Dis. 2018; 24(7):1589-1596. DOI: 10.1093/ibd/izy051. View

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W . Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22(1):63. PMC: 8919523. DOI: 10.1186/s12902-022-00980-1. View

Abenavoli L, Spagnuolo R, Scarlata G, Scarpellini E, Boccuto L, Luzza F . Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study. Medicina (Kaunas). 2023; 59(11). PMC: 10673463. DOI: 10.3390/medicina59111935. View

10.

Yang A, Zhu X, Zhang L, Ding Y . Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort. J Hepatol. 2023; 80(4):e154-e155. DOI: 10.1016/j.jhep.2023.09.033. View

11.

Martinez-Dominguez S, Garcia-Mateo S, Gargallo-Puyuelo C, Gallego-Llera B, Callau P, Mendi C . Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals. Inflamm Bowel Dis. 2023; 30(8):1274-1283. PMC: 11291618. DOI: 10.1093/ibd/izad175. View

12.

Lin Y, Feng X, Cao X, Miao R, Sun Y, Li R . Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. Diabetol Metab Syndr. 2022; 14(1):181. PMC: 9706887. DOI: 10.1186/s13098-022-00930-w. View

13.

Simon T, Roelstraete B, Hagstrom H, Loomba R, Ludvigsson J . Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study. J Hepatol. 2023; 79(6):1366-1373. PMC: 11146347. DOI: 10.1016/j.jhep.2023.08.008. View

14.

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View

15.

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

16.

Perazzo H, Pacheco A, Griep R . Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J Hepatol. 2023; 80(2):e72-e74. DOI: 10.1016/j.jhep.2023.08.025. View

17.

Fairbrass K, Costantino S, Gracie D, Ford A . Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(12):1053-1062. DOI: 10.1016/S2468-1253(20)30300-9. View

18.

De Caro C, Spagnuolo R, Quirino A, Mazza E, Carrabetta F, Maurotti S . Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study. Int J Mol Sci. 2024; 25(10). PMC: 11121796. DOI: 10.3390/ijms25105453. View

19.

Choi J, Sohn W, Cho Y . The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020; 26(4):662-669. PMC: 7641550. DOI: 10.3350/cmh.2020.0163. View

20.

Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T . Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014; 2(5):633-636. PMC: 4106613. DOI: 10.3892/br.2014.309. View